TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20876171

Group type: EXPERIMENTAL
Intervention: Nebulized epinephrine plus oral dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: No active treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nebulized epinephrine alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral dexamethasone alone
Number of subjects: 0
Study: 18722297

Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty (THA)
Number of subjects: 40
Study: 16151035

Group type: EXPERIMENTAL
Intervention: Treadmill aerobic training (T‐AEX)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Reference rehabilitation program of stretching plus low‐intensity walking (R‐CONTROL)
Number of subjects: 61
Study: 12570938

Group type: EXPERIMENTAL
Intervention: Fasudil (4.5 mg intracoronarily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline (control group, n = 5)
Number of subjects: 18
Study: 10212743

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PYR) 45 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8901300

Group type: EXPERIMENTAL
Intervention: Hysteroscopic metroplasty
Number of subjects: 5
Study: 1991701

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at a dose of 250 mg/m2/day for 12 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Conventional radiation therapy
Number of subjects: 18
Study: 6127861

Group type: EXPERIMENTAL
Intervention: Nadolol 2% solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: Timolol 0.25% solution
Number of subjects: 10
Study: 30676480

Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 8342
Study: 30257069

Group type: EXPERIMENTAL
Intervention: Luces de Cambio intervention (12-month family-based culturally tailored behavioral intervention)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 297
Study: 26526421

Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 138

Group type: COMPARATOR
Intervention: Incomplete revascularization
Number of subjects: 138

Group type: COMPARATOR
Intervention: Post-operative complications, 30-day mortality, or 3-year survival
Number of subjects: 138
Study: 24841107

Group type: EXPERIMENTAL
Intervention: Anticyclic modulated ventilation (ACMV)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 39
Study: 23112415

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 24
Study: 19528154

Group type: EXPERIMENTAL
Intervention: 3 day amoxicillin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7 day amoxicillin treatment
Number of subjects: 0
Study: 17325591

Group type: EXPERIMENTAL
Intervention: Nilvadipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 12
Study: 15140737

Group type: EXPERIMENTAL
Intervention: Dual T2-weighted fast spin-echo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: T2-weighted fat-suppressed fast spin-echo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced T1-weighted fat-suppressed spin-echo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Unenhanced and contrast-enhanced 3D time-of-flight MR angiography
Number of subjects: 31
Study: 11571980

Group type: EXPERIMENTAL
Intervention: early postoperative intraperitoneal mitomycin C and 5-fluorouracil
Number of subjects: 248

Group type: COMPARATOR
Intervention: surgery only
Number of subjects: 248
Study: 10193369

Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg orally twice per day for four weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 7822908

Group type: EXPERIMENTAL
Intervention: Nerve reconnection technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Original Littler technique
Number of subjects: 30
Study: 3342287

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deuterium-labelled lidocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deuterium-labelled bupivacaine
Number of subjects: 0
Study: 30335712

Group type: EXPERIMENTAL
Intervention: Web-based progressive cervical strengthening program
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study: 30571173

Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (15 mg/wk)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 27475837

Group type: EXPERIMENTAL
Intervention: Icon condition (acetaminophen medications marked with an icon)
Number of subjects: 517

Group type: COMPARATOR
Intervention: Non-icon condition (current labeling)
Number of subjects: 517
Study: 24273022

Group type: EXPERIMENTAL
Intervention: Epratuzumab 360 mg/m2
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Epratuzumab 720 mg/m2
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 23085132

Group type: EXPERIMENTAL
Intervention: Direct mailing of DXA results and educational brochure
Number of subjects: 7500

Group type: COMPARATOR
Intervention: Usual care (standard practice)
Number of subjects: 7500
Study: 22027612

Group type: EXPERIMENTAL
Intervention: Adaptol 500 mg, 2 times daily in addition to regular vasoactive treatment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Regular treatment (control group)
Number of subjects: 68
Study: 19006592

Group type: EXPERIMENTAL
Intervention: Colchicine mouthwash (2 mg daily for 5 days)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 82
Study: 16796402

Group type: EXPERIMENTAL
Intervention: On-site rapid HIV testing at occupational clinics
Number of subjects: 7482

Group type: COMPARATOR
Intervention: Off-site VCT using vouchers for rapid tests at free-standing centres
Number of subjects: 7482
Study: 14570343

Group type: EXPERIMENTAL
Intervention: Cefazolin plus metronidazole (1 g cefazolin + 500 mg metronidazole)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Cefazolin (2 g)
Number of subjects: 160
Study: 10817729

Group type: EXPERIMENTAL
Intervention: 600 mg of abacavir
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.7 g of ethanol per kg of body weight
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 600 mg of abacavir and 0.7 g of ethanol per kg
Number of subjects: 25
Study: 8872401

Group type: EXPERIMENTAL
Intervention: Half-age energy dosing (7 J, 30% higher than titration estimates)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Threshold titration
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Half-age energy dosing
Number of subjects: 35

Group type: COMPARATOR
Intervention: Threshold estimation strategy
Number of subjects: 35
Study: 1325574

Group type: EXPERIMENTAL
Intervention: Pre-operative chemotherapy (4 weeks or 8 weeks arm of treatment with ACT D and VCR)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Pre-operative chemotherapy
Number of subjects: 188
Study: 6380982

Group type: EXPERIMENTAL
Intervention: Antacid
Number of subjects: 21

Group type: COMPARATOR
Intervention: Secretin
Number of subjects: 21
Study: 30229405

Group type: EXPERIMENTAL
Intervention: Single coil shock vector
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Dual coil shock vector
Number of subjects: 216

Group type: COMPARATOR
Intervention: All successive internal shocks
Number of subjects: 216

Group type: COMPARATOR
Intervention: Predictors of first shock failure
Number of subjects: 216
Study: 30184600

Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy (CN) followed by interferon therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy (CN) followed by sunitinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palliative nephrectomy (PN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angioembolisation
Number of subjects: 0
Study: 27624781

Group type: EXPERIMENTAL
Intervention: PBMT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PBMT + cryotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cryotherapy + PBMT
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 24592952

Group type: EXPERIMENTAL
Intervention: Oral zinc gluconate (26 mg zinc twice daily for 14 days)
Number of subjects: 0
Study: 23303986

Group type: EXPERIMENTAL
Intervention: Diazoxide 100 mg orally three times daily for 10 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (matched controls without PCOS)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Diazoxide treatment
Number of subjects: 17
Study: 20716348

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma and standard-of-care fixation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care fixation alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed-angle screw and plate fixation system
Number of subjects: 0
Study: 18038603

Group type: COMPARATOR
Intervention: Standard antituberculosis therapy (Group 1)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Standard antituberculosis therapy + paravasal lymphotrophic immunological correction (Group 2)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Individual regimens of antituberculous drugs (Group 3)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Individual regimens during immunological correction (Group 4)
Number of subjects: 154
Study: 15788294

Group type: EXPERIMENTAL
Intervention: Single-reading arm (radiographs interpreted by an oncologist only)
Number of subjects: 869

Group type: COMPARATOR
Intervention: Double-reading arm (oncologist and then a radiologist independently interpreted plain radiographs)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Single-reading arm
Number of subjects: 869
Study: 15510746

Group type: EXPERIMENTAL
Intervention: FK‐506 eyedrops (0.5 mg/ml) and TobraDex eyedrops
Number of subjects: 56

Group type: COMPARATOR
Intervention: 1% CsA eyedrops and TobraDex eyedrops
Number of subjects: 56
Study: 9805320

Group type: EXPERIMENTAL
Intervention: Working memory task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vigilance task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Performance and degree of activation
Number of subjects: 0
Study: 7625343

Group type: EXPERIMENTAL
Intervention: Experimental group fed formulas with protein-energy ratios of 3.73 g/MJ (1.56 g/100 kcal) from 8 to 27 days, decreasing to 2.99 g/MJ (1.25 g/100 kcal) from 84 to 111 days.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (details not specified in the abstract).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference group (details not specified in the abstract).
Number of subjects: 0
Study: 2476759

Group type: EXPERIMENTAL
Intervention: Medtronic 6957J lead with an electrically active myocardial screw‐helix
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cordis 329‐101P lead with an inactive helix and a porous tip electrode
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medtronic 6957J lead
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cordis 329‐101P lead
Number of subjects: 0
Study: 357213

Group type: EXPERIMENTAL
Intervention: Ro 10‐9359 at 25 mg t.i.d.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ro 10‐9359 at 50 mg b.i.d.
Number of subjects: 27
Study: 29745885

Group type: EXPERIMENTAL
Intervention: Tocilizumab plus methotrexate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not achieving sDFR)
Number of subjects: 60
Study: 28063805

Group type: EXPERIMENTAL
Intervention: Prenatal Counseling Group (PCG)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Overall rates of breastfeeding in PCG
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Overall rates of breastfeeding in CG
Number of subjects: 171
Study: 25762753

Group type: EXPERIMENTAL
Intervention: Smoking cues
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Stress cues
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Post-stress cue craving
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Post-stress cue stress
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Post-stress cue negative affect
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Response to smoking cues
Number of subjects: 76
Study: 23684358

Group type: EXPERIMENTAL
Intervention: MIROX strategy (6 FOLFOX7 cycles followed by 6 FOLFIRI cycles)
Number of subjects: 39

Group type: COMPARATOR
Intervention: sLV5FU2 (12 cycles of simplified LV5FU2)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: MIROX strategy
Number of subjects: 39
Study: 20495110

Group type: EXPERIMENTAL
Intervention: Low-density gas mixture (60% helium and 40% O₂)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: O₂ supplementation (40%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 30
Study: 18381513

Group type: EXPERIMENTAL
Intervention: Hypothermia (33 degrees C to 34 degrees C) for 72 hours with continuous morphine infusion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normothermia with continuous morphine infusion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hypothermia with morphine infusion rate >10 microg/kg per h
Number of subjects: 16
Study: 17079365

Group type: EXPERIMENTAL
Intervention: Core decompression group
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nonoperative group
Number of subjects: 33

Group type: COMPARATOR
Intervention: Combined necrotic angle of </=190 degrees (low-risk group)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Combined necrotic angle of >/=240 degrees (high-risk group)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Combined necrotic angle between 190 degrees and 240 degrees (moderate-risk group)
Number of subjects: 33
Study: 12690024

Group type: EXPERIMENTAL
Intervention: Responsible sexuality education programme (RSP)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 399
Study: 11910617

Group type: EXPERIMENTAL
Intervention: Soy protein dietary supplements containing 118 mg of isoflavones (daidzein, genistein, glycitein and their respective glycosides)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo (casein)
Number of subjects: 94
Study: 8834027

Group type: EXPERIMENTAL
Intervention: Propranolol therapy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Recent bleeding episode
Number of subjects: 98

Group type: COMPARATOR
Intervention: Non-bleeders
Number of subjects: 98
Study: 1282364

Group type: EXPERIMENTAL
Intervention: Interferon alpha therapy (3 million units daily for the first month, then thrice weekly for 5 months)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Interferon alpha therapy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Interferon alpha therapy and Control group
Number of subjects: 10
Study: 6374403

Group type: EXPERIMENTAL
Intervention: Triple intrathecal (IT) chemotherapy (methotrexate, hydrocortisone, cytosine arabinoside) starting on day 1 of treatment (Arm 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other regimens (Arms 1, 2, and 4) where CNS prophylaxis was initiated after complete marrow remission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple IT chemoprophylaxis during induction therapy (Arm 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other regimens (Arms 1, 2, and 4)
Number of subjects: 0
Study: 30316185

Group type: EXPERIMENTAL
Intervention: Video game training (15 hours over five weeks)
Number of subjects: 35
Study: 29669139

Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg + furosemide 20 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Nutritional counseling to sodium-restricted diet plus placebo pill
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 54
Study: 26482684

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 105

Group type: COMPARATOR
Intervention: Modified Ranawat suspension
Number of subjects: 105
Study: 24313446

Group type: EXPERIMENTAL
Intervention: Action and coping planning strategies (n = 59)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Usual care (n = 56)
Number of subjects: 115
Study: 23044294

Group type: COMPARATOR
Intervention: Permanent polymer sirolimus-eluting stent (PP-SES)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Polymer free paclitaxel-eluting stent (PF-PES)
Number of subjects: 105
Study: 19540483

Group type: EXPERIMENTAL
Intervention: Testicular sperm extraction (TESE)
Number of subjects: 57
Study: 17432691

Group type: EXPERIMENTAL
Intervention: Tiaoshen Tonglin Decoction (TTD) for 60 days
Number of subjects: 108

Group type: COMPARATOR
Intervention: Terazosin tablet for 60 days
Number of subjects: 108
Study: 16535996

Group type: EXPERIMENTAL
Intervention: Alfacalcidol 5 micrograms/day for 5 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (healthy subjects and NIND patients)
Number of subjects: 15
Study: 12010650

Group type: EXPERIMENTAL
Intervention: Iscador Quercus special (IQ)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Iscador Pini (IP)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 10363731

Group type: EXPERIMENTAL
Intervention: bupropion SR 150 to 400 mg/d
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: sertraline 50 to 200 mg/d
Number of subjects: 360

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 360
Study: 7734255

Group type: EXPERIMENTAL
Intervention: 1% mepivacaine with adrenaline 40 ml, arm adducted
Number of subjects: 90

Group type: COMPARATOR
Intervention: 1% mepivacaine with adrenaline 40 ml, arm abducted
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2% mepivacaine 20 ml mixed with contrast agent 20 ml, arm adducted
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2% mepivacaine 20 ml mixed with contrast agent 20 ml, arm abducted
Number of subjects: 90
Study: 2041002

Group type: EXPERIMENTAL
Intervention: Binaural hearing aid fitting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monaural hearing aid fitting
Number of subjects: 0
Study: 6112602

Group type: EXPERIMENTAL
Intervention: D-penicillamine (600 mg daily)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 31726240

Group type: EXPERIMENTAL
Intervention: Multisensory linear
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Multisensory random
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Visual linear
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Visual random
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control
Number of subjects: 85
Study: 30516413

Group type: EXPERIMENTAL
Intervention: Power brush/irrigator/mouthrinse routine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Dental prophylaxis followed by regular manual brushing
Number of subjects: 51
Study: 28594575

Group type: EXPERIMENTAL
Intervention: Bolus calculator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bolus calculator (extended use from 4 to 8 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (previously intensified treatment)
Number of subjects: 0
Study: 25823544

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target SBP <140 mm Hg)
Number of subjects: 3243

Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure lowering (target SBP <180 mm Hg)
Number of subjects: 3243
Study: 23609769

Group type: EXPERIMENTAL
Intervention: Ecstasy users (12)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ecstasy + amphetamine users (10)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Controls (26 for orientation tuning; 38 for contour detection)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ecstasy + amphetamine users (12)
Number of subjects: 38
Study: 21410481

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 19374211

Group type: EXPERIMENTAL
Intervention: Ephedrine (Group E, n = 30, dose = 10 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Phenylephrine (Group P, n = 30, dose = 80 microg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ephedrine (Group E)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Phenylephrine (Group P)
Number of subjects: 60
Study: 17919246

Group type: EXPERIMENTAL
Intervention: Physical therapy (group II)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Michigan splint (group I)
Number of subjects: 26
Study: 15119720

Group type: EXPERIMENTAL
Intervention: Loop technique
Number of subjects: 45

Group type: COMPARATOR
Intervention: Holder technique
Number of subjects: 45
Study: 11326796

Group type: EXPERIMENTAL
Intervention: Calcium intake of 900 mg/day
Number of subjects: 0
Study: 9565434

Group type: EXPERIMENTAL
Intervention: Preventive use of SnMP (6 micromol/kg birth weight, intramuscularly)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Therapeutic use of SnMP (6 micromol/kg birth weight, intramuscularly)
Number of subjects: 86
Study: 8200238

Group type: EXPERIMENTAL
Intervention: Regular diet on the first postoperative morning (Group 1)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Traditional feeding method (Group 2)
Number of subjects: 64
Study: 3310631

Group type: EXPERIMENTAL
Intervention: Sucralfate therapy, 1 g four times daily
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Sucralfate therapy, 1 g twice daily to 1 g four times daily (long-term)
Number of subjects: 143
Study: 29895557

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (standard treatment without empagliflozin)
Number of subjects: 50
Study: 27183970

Group type: EXPERIMENTAL
Intervention: Vectra® 3D (54.45 mg/ml of dinotefuran, 396.88 mg/ml of permethrin and 4.84 mg/ml of pyriproxyfen)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vectra® 3D
Number of subjects: 24

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 24